Champions Oncology (2I3) Q1 2027 Earnings Report

The call was strongly positive overall. Management reported approximately 9% revenue growth, significant gross and oncology services margin expansion, the fifth consecutive quarter of positive adjusted EBITDA, stronger data licensing revenue, healthy services demand, and continued Corellia progress. The main cautions were the remaining GAAP net loss, cash usage, lumpy timing of data licensing revenue, higher sales and marketing expense from planned investment, and uncertainty around the timing of a Corellia funding or licensing outcome.

For fiscal '27, management said it has 3 more quarters to prove out the progress and will keep reporting against it in the same way each time, with a focus on continuing to grow revenue while expanding profitability, maintaining expense discipline, and converting revenue growth into improved profitability; expected conversion percentages remain strong, data license revenue will remain lumpy, and pipeline continues to be robust. Management said it was not going to put a date on any Corellia outcome, but if successful in securing outside funding or a licensing partnership, the investment currently flowing into that business would be redeployed toward other growth initiatives, particularly data and to the bottom line.